Publicaciones científicas

Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma

06-nov-2018 | Revista: Oncotarget

Steven Georges, Lidia Rodriguez Calleja, Camille Jacques, Melanie Lavaud, Brice Moukengue, Fernando Lecanda, Thibaut Quillard, Marta Tellez Gabriel, Pierre-François Cartron, Marc Baud'huin, François Lamoureux, Dominique Heymann, Benjamin Ory


The metastatic dissemination is a complex multistep process by which tumor cells from a primary site enter into the systemic circulation to finally spread at distant sites. Even if this mechanism is rare at the tumor level, it remains the major cause of Osteosarcoma-patients' relapse and mortality. MicroRNAs (miRNAs) have recently been described as novel epigenetics' genes' expression regulators actively implicated in cancer progression and dissemination.

The understanding of their implication in the metastatic spreading could help clinicians to improve the outcome of osteosarcoma. We established the miRNA's expression-profile between primary bone-tumors (PTs), circulating tumor cells (CTCs) and lung metastatic (META) samples from in vivo mice xenograft models. Our results show that the expression level of the miR-198 and -206 was decreased in META samples, in which the expression of the metastasis-related receptor C-Met was up-regulated. Those expression variations were validated in osteosarcoma patient biopsies from matching primary tumors and lung metastasis.

We validated in vitro the endogenous miRNAs inhibitory effects on both migration and invasion, as well as we confirmed by luciferase assays that the C-Met receptor is one of their bona-fide targets. The anti-metastatic effect of these miRNAs was also validated in vivo, as their direct injections into the tumors reduce the number of lung-metastases and prolongs the overall survival of the treated animals. All together, our results suggest the absence of the miR-198 and -206 as powerful predictive biomarkers of the tumor cell dissemination and the rationale of their potential therapeutic use in the treatment of Osteosarcoma.

CITA DEL ARTÍCULO  Oncotarget. 2018 Nov 6;9(87):35726-35741. doi: 10.18632/oncotarget.26284.